Source: Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Tim Lahm, Steven M. Kawut. Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research. Eur Respir J, 50 (2) 1700983; 10.1183/13993003.00983-2017

Member's Comments

No comment yet.

Related content which might interest you: Current medical therapies in pulmonary arterial hypertension Source: Eur Respir Mon 2012; 57: 26-41 Year: 2012 Goal-oriented treatment and combination therapy for pulmonary arterial hypertension Source: Eur Respir J 2005; 26: 858-863 Year: 2005 Leptin signalling system as a target for pulmonary arterial hypertension therapy Source: Eur Respir J 2015; 45: 1066-1080 Year: 2015 Olfactory receptors in pulmonary arterial hypertension: A novel pathway of vascular remodeling? Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Beyond oestrogens: towards a broader evaluation of the hormone profile in pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1801058; 10.1183/13993003.01058-2018 Year: 2018 Regulation of Type I cytokine receptors as a target for pulmonary arterial hypertension treatment? Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Oestrogen and the sexual dimorphism of pulmonary arterial hypertension: a translational challenge Source: Eur Respir J 2013; 41: 1014-1016 Year: 2013 Obesity alters oestrogen metabolism and contributes to pulmonary arterial hypertension Source: Eur Respir J, 53 (6) 1801524; 10.1183/13993003.01524-2018 Year: 2019 Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects Source: Eur Respir J, 50 (2) 1602337; 10.1183/13993003.02337-2016 Year: 2017 The use of combination therapy in pulmonary arterial hypertension: new developments Source: Eur Respir Rev 2009; 18: 148-153 Year: 2009 Oestradiol ameliorates monocrotaline pulmonary hypertension via NO, prostacyclin and endothelin-1 pathways Source: Eur Respir J 2013; 41: 1116-1125 Year: 2013 Complexities of oestradiol pharmacology in pulmonary arterial hypertension Source: Eur Respir J 2013; 41: 1465-1466 Year: 2013 Complexities of oestradiol pharmacology in pulmonary arterial hypertension Source: Eur Respir J 2013; 41: 1466-1467 Year: 2013 Beyond a single pathway: combination therapy in pulmonary arterial hypertension Source: Eur Respir Rev 2016; 25: 408-417 Year: 2016 PSGR olfactory receptor: A new potential target in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy Source: Eur Respir Rev 2009; 18: 253-259 Year: 2009 Dysregulation of TGF-β/BMP signaling in a monocrotaline model of pulmonary hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases Source: Eur Respir J 2008; 31: 343-348 Year: 2008 Sex matters in pulmonary arterial hypertension Source: Eur Respir J 2014; 44: 553-554 Year: 2014 Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011